beigene co ltd
Ambrx And BeiGene To Jointly Develop Next-Gen Biologics
Under the terms of the collaboration with BeiGene, Ambrx will receive US$10 million to fund the initial discovery and research activities for novel biologic drug candidates.
Celgene Buys The Rights To BeiGene’s Checkpoint Inhibitor
BeiGene will acquire Celgene's commercial operations in China and exclusive license to Celgene's China cancer commercial portfolio.
BeiGene Receives US$320 Million To Build Biologics Facility In China
BeiGene Co. Ltd. and Guangzhou Development District have entered into a joint venture worth US$330 million to build a state-of-the-art biologics manufacturing plant.
BeiGene Closes US$200 Million Public Offering
The biopharmaceutical company, which develops immuno-oncology drugs, has announced the closing of its follow-on public offering of 6,250,000 American Depositary Shares.
Phase I Trial For BeiGene’s PARP Inhibitor Begins
BeiGene's PARP inhibitor BGB-290 could be an important treatment for common cancers such as gastric cancer and primary brain tumors.
Merck & BeiGene To Co-Develop 2nd Gen BRAF Inhibitor
Merck Serono and BeiGene have agreed to co-develop a second-generation BRAF inhibitor for the treatment of cancer.
